ABSTRACT
INTRODuCTION
In recent years, it has been estimated that 30-50% of patients with heart failure (HF) have preserved ejection fraction (HFpEF). These patients have a poor prognosis, have more frequently atrial fibrillation (AF), and are more likely to be older, women, hypertensive, and anemic compared to HF patients with reduced ejection fraction (HFrEF).
1,2 The current therapy available for this group of patients includes a decrease in loading conditions, treatment of comorbidities, which can lead to a reduction in symptom severity and increase in functional capacity, thus preventing rehospitalizations. Although tolvaptan (TLV) has been previously investigated in patients with HF, there are currently few studies that have discussed its long-term efficacy in elderly patients with HFpEF. [3] [4] [5] [6] [7] [8] [9] [10] The aim of this study was to evaluate the short-and long-term clinical efficacy of TLV for treating elderly patients with HFpEF.
METHODS
This retrospective observational study involved all consecutive HFpEF patients hospitalized at the Nagoya Heart
Center, Japan, from 2013 to 2017. Inclusion criteria for this study were as follows: (1) patients aged ≥75 years; (2) first hospitalization secondary to acute decompensated heart failure (ADHF); (3) patients who had received medical therapy for HF, without invasive treatments such as cardiac surgery or catheter-based intervention; and (4) patients who were clinically followed up for >6 months after discharge. Exclusion criteria for this study were mechanical ventilation, cardiogenic shock, dialysis, and malignancy.
To diagnose HF, we used the Framingham criteria.
11
With regard to the definition of HFpEF, we employed the European Society of Cardiology (ESC) guidelines and used Doppler echocardiography to establish the diagnoses. Echocardiography was performed within 24 hours after hospitalization. 12 In this study, we defined HFpEF according to the following criteria: (1) signs or symptoms of HF; and (2) LVEF ≥50% as determined by trans-thoracic echocardiography.
The primary endpoint of this study was rehospitalization due to worsening HF, and the secondary endpoints were worsening renal function (WRF) during hospitalization and at 6 months after discharge. WRF was defined as ≥0.3 mg/dL increase in serum creatinine level above the baseline at any time during hospitalization and at 6 months after discharge. The bed rest period was defined as the time interval between the day of admission and the day on which cardiac rehabilitation was initiated in the rehabilitation room. The congestion scale included a standard 4-point scoring system4 in which clinical features were comprised of heart failure signs and symptoms (shortness of breath, distended jugular venous system, pulmonary congestion, and lower limb edema), and the score was evaluated at baseline and at 3 and 6 months after discharge. The congestion score was calculated by summing the individual scores.
After applying the inclusion and exclusion criteria, the patients were divided into 2 groups: with TLV therapy (TLV (+) group) and without TLV therapy (TLV (-) group).
Informed consent was obtained from each patient, and the hospital ethics committee approved this study. The timing and dosage of TLV therapy of each patient were at the discretion of their attending physician.
The present study complies with the Declaration of Helsinki, and the institutional review board of our institute has approved the research protocol. Informed consent was obtained from all participants before enrollment into the study.
StatiStical analySiS
Continuous data are presented as mean ± SD. All differences were compared using Student's t-test and nonparametric methods. Discrete variables are expressed as counts and percentages. These were assessed using Fisher's exact test or the chi-squared test, depending on the sample size. Multivariate logistic regression analysis was applied to identify the risk for rehospitalization. Time-toevent data were summarized as Kaplan-Meier estimates according to the rehospitalization status and were compared using the log-rank test. Propensity score matching analysis was adopted for eligible patients to select the background-matched control population. In all analyses, p <0.05 was considered to indicate statistical significance.
Statistical analyses were performed using SPSS version 23
(IBM Corp., Armonk, NY, USA).
RESuLTS
A total of 377 consecutive first-hospitalized ADHF patients were treated at the Nagoya Heart Center between 2013 and 2017. Among these patients, 118 had undergone invasive therapies, whereas the remaining 259 patients received medical therapy. Among these 259 patients, 100
patients were diagnosed with HFpEF. After propensity score matching analysis, we enrolled 60 HFpEF patients into this study. The TLV (+) and (−) groups comprised 29
and 31 patients, respectively. The proportion of patients who started TLV therapy from the first day of hospitalization was 82.8%, and all patients treated with TLV continued the therapy even after discharge.
The baseline characteristics and the clinical outcomes are shown in Table 1 . There was no difference in the base- of loop diuretics at both discharge and at 6 months after discharge, as well as serum creatinine level at 6 months after discharge, were significantly lower in the TLV (+) group. Although there was no difference in the congestion score at discharge, it was significantly higher in the TLV (−) group at 6 months after discharge. The level of NTproBNP was also significantly higher in the TLV (−) group at 6 months after discharge. As shown in Figure 1 , the in- Kaplan-Meier analysis revealed that the incidence of rehospitalization was significantly lower in the TLV (+) group than in the TLV (−) group (log-rank test; p = 0.018) ( Figure 2 ). As shown in 
DISCuSSION
This study demonstrated the efficacy of TLV therapy for elderly HFpEF patients. The main findings of the study were as follows: (1) 
WRF development
Previous studies have reported that WRF often occurred in subjects that had been admitted to the hospital for HF and was associated with an increased rate of adverse events. 13 18, 19 In our study, 82.8% of the patients started TLV therapy from the first day of hospitalization, and TLV therapy reduced loop diuretics doses both at discharge and after 6 months, and it also prevented WRF development until 6 months group, the incidence of WRF development has increased from 3.4% at baseline to 13.3% at the 6-month follow-up.
The fact that the dose of loop diuretic increased after 6 months compared to the dose at discharge might indicate that TLV therapy could contribute to WRF development, and further studies are necessary to address this finding.
Bed ReSt peRiod
Older patients with HF are more likely to be hospitalized and are at risk of functional decline during hospitalization.
A previous study has reported that there was a considerable loss of skeletal muscle, particularly from the lower extremities, as a result of bed rest. 20 Uemura et al. demonstrated that physical activity at discharge independently predicted subsequent poor prognosis in HF patients. 21 The prevention of functional decline during hospitalization is a very important issue, and the bed rest period should be as short as possible. Ueda et al. reported that an early switch from continuous intravenous infusion to oral medication significantly prevented the functional decline during hospitalization. 22 In our study, 82.8% of the patients started TLV therapy from the first day of hospitalization, and the duration of continuous intravenous infusion was significantly shorter in patients treated with TLV therapy.
As a result, the bed rest period was significantly shorter in these elderly patients treated with TLV. These results suggest that TLV immediately improves systemic congestion and shortens both the bed rest period and the length of hospital stay, and might be able to prevent frailty in elderly patients with HF.
RehoSpitalization Rate
Imamura and Kinugawa demonstrated that TLV therapy significantly decreased the incidence of rehospitalization in patients with HFpEF. 23 Consistently, the current study demonstrated that TLV therapy reduced the incidence of rehospitalization in HFpEF patients, and TLV therapy after discharge was the predictive factor for rehospitalization. Previous studies have demonstrated the burden of recurrent congestion even after the initial relief of congestion during acute hospitalization. 24, 25 In both studies, clinical outcomes were superior for subjects with no or mild remaining congestion, while prognosis was significantly impaired in individuals with important remaining congestion at discharge. In this study, although there was no difference in the congestion score at discharge between the TLV (+) and TLV (−) groups, the congestion score was significantly higher in the TLV (−) group at 6 months after discharge. The ambulatory administration of TLV seems to continue to suppress recurrent congestion and prohibit the worsening of HF.
There are several limitations in this study. First, this was a retrospective observational study conducted at a single center, and the number of study participants was small; therefore, the statistical power might be low.
Hence, the findings should be confirmed in a multi-center, large-scale, randomized study in the future. Second, each attending physician independently decided the timing and dosage of TLV, because an appropriate dose for each patient is essential for a successful HF management. 
